



## SFA Spotlight - December 2018

*Welcome to our newsletter! Please be on the lookout for this newsletter every month as a way to keep you more involved and engaged with information important to the SFA community.*

*Please be sure to include [info@curesarcoma.org](mailto:info@curesarcoma.org) in your address book. If you do not wish to receive this email on a monthly basis, please [contact us](#).*



## Nearly \$1 Million Raised Through RTCS in 2018!

THANK YOU to all of the participants, donors, sponsors and supporters who helped to make the 2018 Race to Cure Sarcoma (RTCS) season such a success! **More than 5,000 people in 12 cities joined forces to help raise nearly \$1 million for sarcoma research!** Money raised through these events supports research nationally through the SFA's [research grant program](#) and locally through the efforts of our partner sarcoma centers.



**RACE TO CURE  
SARCOMA™**  
Sarcoma Foundation of America



Here are a few highlights from 2018:

#### Most Participants

More than 800 people participated in the [Race to Cure Milwaukee](#).

#### Largest Fundraising Total

The Race to [Cure Sarcoma Chicago](#) raised a record-breaking \$252,000.

#### Top Three RTCS Teams

1. Team Langbein ([RTCS Chicago](#))
2. Team Crafton ([RTCS Nashville](#))
3. Team Chris ([RTCS San Francisco](#))

#### Newest RTCS Events

The Race to Cure Series grew this year with inaugural events held in [Atlanta](#), [Cleveland](#), [Kansas City](#), [Tampa](#) and [San Francisco](#).

#### Returning Events Celebrate 2nd and 3rd Anniversaries

Our returning events all had spectacular years! [Denver](#), [Philadelphia](#), and [Chicago](#) each celebrated their third annual event, with [Milwaukee](#), [Nashville](#), [New Jersey](#), and [Richmond](#) hosting the Race to Cure Sarcoma for a second year.

The Race to Cure Sarcoma depends on the support of our sarcoma community and we could not have done this without you. We look forward to seeing you all again for the 2019 season!



## SFA Funds New Research in Uterine Leiomyosarcoma

In November, the Sarcoma Foundation of America announced the award of two research grants for projects focused on the study of uterine leiomyosarcoma. Made possible by the generosity of the Dr. Richard and Valerie Aronsohn Memorial Fund, these awards support investigative efforts by leading sarcoma researchers at Memorial Sloan-Kettering Cancer Center and Stanford University.

“The Sarcoma Foundation of America is proud to lead this effort to support much needed research for uterine leiomyosarcoma and we are excited to collaborate with Drs. Tap, D’Angelo, and van de Rijn on their innovative projects,” said Richard Rumsey, CEO, Sarcoma Foundation of America. “This research helps fulfill the legacies of Dr. and Mrs. Aronsohn, who sought to find the cure for this devastating subtype of sarcoma.”

To read more about these research awards, visit <https://www.curesarcoma.org/uterine-leiomyosarcoma-research-grants/>.



Thank you to all who have so generously supported the Sarcoma Foundation of America this year! Your contributions have helped us accomplish so much in 2018. Together, we continue the work

Thinking about making a year-end gift? There's still time! To qualify for a tax deduction in the 2018 calendar year, donation forms and checks/money orders sent by mail must be postmarked on or before December 31, 2018. Ready to donate today? You can make your contribution at [www.curesarcoma.org/match](http://www.curesarcoma.org/match).

## Sarcoma Foundation of America Sarcoma Research Grant Program

The Sarcoma Foundation of America (SFA) is now accepting research grant proposals. Grants of \$50,000, allowing up to 10 percent indirect costs, are available to cover equipment and supplies in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas.

**The SFA will only accept applications that focus on the following areas of research:**

- \* Omic characterization of sarcomas and definition of novel targets
- \* Omic patterns of sensitivity and resistance to existing agents
- \* Systemic therapy combinations
- \* Immunotherapy

The SFA raises funds to support basic research focused on discovering and developing new and effective therapies to treat and eradicate sarcoma.



Application deadline is January 31, 2019.

For details and guidelines, please visit  
[www.curesarcoma.org/research/apply-for-a-grant/](http://www.curesarcoma.org/research/apply-for-a-grant/).

### New Drug Tested in Soft Tissue Sarcoma Approved by FDA

There is a new tool in the fight against soft tissue sarcoma. In late November, the U.S. Food and Drug Administration (FDA) approved Vitakvi (larotrectinib), a TRK inhibitor, for the treatment of both adult and pediatric patients with solid tumors that have an NTRK gene fusion. The FDA cited soft tissue sarcomas as one of the cancer types that responded to the drug in clinical trials. More information on the approval can be found at

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626710.htm>.

## You can purchase with purpose this holiday season

Buy your holiday gift and supplies at [smile.amazon.com](https://smile.amazon.com) and Amazon donates

You shop. Amazon donates.  
**amazon**smile



Wrap up your holiday shopping at [smile.amazon.com/ch/52-2275294](https://smile.amazon.com/ch/52-2275294) and AmazonSmile donates to The Sarcoma Foundation of America.

*Stay Connected!*  
**FOLLOW SFA  
ON  
SOCIAL MEDIA**

@CURESARCOMA  
#CURESARCOMA



### Our mailing address is:

9899 Main Street, Suite 204, Damascus, MD 20872

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).